- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04898777
EUS-Guided Choledochoduodenostomy Versus ERCP for Primary Biliary Decompression in Distal Malignant Biliary Obstruction
Endoscopic Ultrasound-Guided Choledochoduodenostomy Versus Endoscopic Retrograde Cholangiopancreatography for Primary Biliary Decompression in Distal Malignant Biliary Obstruction
Malignant biliary obstruction commonly caused by pancreatic adenocarcinoma, cholangiocarcinoma and other etiologies like gallbladder carcinoma, hepatocellular carcinoma, lymphoma, and metastasis to regional solid organs and lymph nodes.
Pancreatobiliary cancers generally present with jaundice, weight loss, and anorexia with significant impact on quality of life, morbidity, and mortality.
The primary goal of diagnosis and management is curative resection but it's difficult due to local invasion and distant metastases at the time of clinical presentation. Biliary decompression helps to reduce symptoms and improve quality of life in patients with malignant biliary obstruction.
Endoscopically placed stents have become the standard of care for non-surgical biliary drainage due to their minimal invasiveness compared to percutaneous drainage.
The standard treatment of obstructive jaundice has been ERCP with biliary stent placement with high success rate in expert hands and low frequency of adverse events.
Endoscopic ultrasound-guided biliary drainage (EUS-BD) has been increasingly used in patients who underwent failed ERCP. EUS-BD can be performed in several ways, choledochoduodenostomy (CDS), hepaticogastrostomy (HGS), antegrade (AG) procedure, and rendezvous (RV) technique.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will be a single center, prospective randomized comparative study that includes 50 patients with distal malignant biliary obstruction including pancreatic head masses, distal cholangiocarcinoma or papillary carcinoma.
All patients with inclusion criteria will be recruited in the study by simple random sampling using sealed envelopes until fulfillment of needed sample size for both EUS-BD arm and ERCP-BD arm.
Study tools:
- Informed consent will be obtained from each participant sharing in the study.
- Throughout history taking, complete general examination and local abdominal examination.
- Laboratory investigations: CBC, Serum creatinine, Liver functions tests (AST, ALT and Serum Albumin), Alkaline phosphatase, Serum bilirubin and INR.
- ERCP-BD by papillary approach and EUS-BD by choledochoduodenostomy with transmural stent placement.
- All procedures will be performed under deep sedation or general anesthesia in the left lateral position.
- Procedural time is recorded.
- Technical success is considered after stent placement (expanded and patent) with good bile flow and drainage.
- Follow up:
- Lab investigations will be requested at 2 days, 2 and 4 weeks, 3 and 6 months after the procedure including:
CBC, S.Cr, S.Bil, AST, ALT, S.Alb, ALP and INR.
- Early adverse events (within 48 hours after procedure) including: Pancreatitis, Cholangitis, Bleeding, Perforation and Peritonitis.
- Late adverse events include stent dysfunction either due to food impaction, tumor ingrowth or stent migration.
- Clinical success is considered at 2 weeks if total bilirubin is less than 50% of baseline and at 4 weeks if total bilirubin is less than 3mg/dL.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ahmed M Gaheen, MSc.
- Phone Number: +201220755170
- Email: gaheen@gmail.com
Study Contact Backup
- Name: Ahmed Y Altonbary, MD
- Phone Number: +201005100091
- Email: Altonbary@gmail.com
Study Locations
-
-
Dakahlia
-
Mansoura, Dakahlia, Egypt, 35516
- Recruiting
- Specialized Medical Hospital
-
Sub-Investigator:
- Ahmed Y Altonbary, MD
-
Contact:
- Ahmed M Gaheen, MSc.
- Phone Number: +201220755170
- Email: gaheen@gmail.com
-
Principal Investigator:
- Ahmed M Gaheen, MSc.
-
Sub-Investigator:
- Hazem H Alminshawy, Professor
-
Sub-Investigator:
- Ahmed G Deiab, A.Professor
-
Sub-Investigator:
- Magdy H Atwa, Professor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age: 18 years and older.
- Presence of locally advanced or metastatic pancreatic head mass on CT or magnetic resonance imaging of the abdomen
- Absence of duodenal obstruction.
- Elevated liver tests with serum bilirubin at least 3 times above the upper limit of normal (1.2 mg/dL).
- Histologic or cytologic diagnosis of malignancy.
- Accept sharing in the study.
Exclusion Criteria:
- Age younger than 18 years.
- Pregnancy.
- Hilar biliary obstruction (as the main lesion or coexisting with distal obstruction).
- Presence of duodenal obstruction.
- Histologic or cytologic diagnosis of malignancy.
- Patients underwent previous intervention for biliary drainage.
- Previously failed biliary cannulation at ERCP.
- Prior biliary sphincterotomy or stent placement.
- Surgically altered anatomy or inability to access the major duodenal papilla.
- Patients unfit for anesthesia.
- Patients having uncorrectable coagulopathy or thrombocytopenia.
- History of allergy to radiocontrast agents.
- Refuse sharing in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: ERCP-BD
ERCP Biliary Drainage by papillary approach with stent placement.
|
Biliary decompression in cases of distal malignant obstruction by stent placement either using ERCP or EUS.
Other Names:
|
Active Comparator: EUS-BD
Endoscopic Ultrasound guided Biliary Drainage by Choledochoduodenostomy with transmural stent placement.
|
Biliary decompression in cases of distal malignant obstruction by stent placement either using ERCP or EUS.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The rate of adverse events
Time Frame: 6 months
|
- Early adverse events (within 48 hours after procedure) including: Pancreatitis, Cholangitis, Bleeding, Perforation and Peritonitis. - Late adverse events include stent dysfunction either due to food impaction, tumor ingrowth or stent migration |
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of technical success
Time Frame: During procedure
|
Technical success is considered after successful stent placement.
|
During procedure
|
Rate of clinical success
Time Frame: 4 weeks
|
Clinical success is considered at 2 weeks if total bilirubin is less than 50 percent of baseline.
|
4 weeks
|
Procedural duration
Time Frame: During procedure
|
Procedure time was defined as time from biliary cannulation to stent placement in ERCP group, and time from needle puncture of the dilated bile duct to stent placement in EUS-BD group.
In cases of difficult cannulation (defined as failed biliary access within 5 min of attempt), we performed early precut fistulotomy for cannulation by experts without involvement of trainees and duodenal intubation time was not included within procedure time.
|
During procedure
|
Reinterventions
Time Frame: 6 months
|
Re-endoscopy in cases of stent migration, occlusion by food or tumor ingrowth.
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Ahmed Y Altonbary, MD, Mansoura University
- Principal Investigator: Ahmed M Gaheen, MSc., Mansoura University
- Study Director: Hazem H Alminshawy, Professor, Mansoura University
- Study Director: Ahmed G Deiab, A.Professor, Mansoura University
- Study Chair: Magdy H Atwa, Professor, Mansoura University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- MD.21.03.437
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Biliary Obstruction
-
Chinese University of Hong KongNot yet recruiting
-
Zagazig UniversityRecruitingMalignant Biliary ObstructionEgypt
-
Seoul National University HospitalRecruitingMalignant Biliary ObstructionKorea, Republic of
-
Tianjin Medical University Cancer Institute and...UnknownMalignant Biliary ObstructionChina
-
Chinese University of Hong KongRecruitingMalignant Biliary ObstructionHong Kong
-
University Hospitals Dorset NHS Foundation TrustThe Christie NHS Foundation TrustRecruitingMalignant Biliary ObstructionUnited Kingdom
-
First People's Hospital of HangzhouCompletedMalignant Biliary ObstructionChina
-
Yonsei UniversityCompletedMalignant Biliary ObstructionKorea, Republic of
-
Johns Hopkins UniversityMedical University of South Carolina; University of Colorado, Denver; All India... and other collaboratorsCompletedMalignant Distal Biliary ObstructionUnited States, India, Japan, Italy, Netherlands
-
Istituto Clinico Humanitas Mater DominiRecruitingDistal Malignant Biliary ObstructionItaly
Clinical Trials on Biliary drainage
-
Institut Paoli-CalmettesCompletedJaundiceFrance, Monaco
-
Hospital Universitari de BellvitgeInstitut d'Investigació Biomèdica de Bellvitge; Fundació Institut de Recerca... and other collaboratorsCompletedPancreatic Cancer | Endoscopy | Oncologic Disorders | Therapy Related NeoplasmsSpain
-
Seoul National University HospitalCompletedBile Duct Cancer | Ampulla of Vater Cancer | Periampullary Cancers With Obstructive Jaundice | Pancreas Head CancerKorea, Republic of
-
Assiut UniversityUnknownMalignant Hepatobiliary Neoplasm
-
Azienda Ospedaliero-Universitaria di ModenaNot yet recruitingBile Duct Diseases | Bile Duct Obstruction | Biliary StonesItaly
-
Tokyo UniversityUnknownJaundiceKorea, Republic of, India, Japan, Thailand, Taiwan, China, Hong Kong, Malaysia, Singapore
-
Theresienkrankenhaus und St. Hedwig-Klinik GmbHUniversity Hospital HeidelbergRecruitingBile Duct Obstruction, ExtrahepaticGermany
-
Tianjin Medical University Cancer Institute and...UnknownPostoperative Complications
-
Central Hospital, Nancy, FranceActive, not recruitingJaundice, Obstructive | Perihilar CholangiocarcinomaFrance
-
First People's Hospital of HangzhouCompletedMalignant Biliary ObstructionChina